EA201300418A1 - Антитела к человеческому tweak и варианты их применения - Google Patents

Антитела к человеческому tweak и варианты их применения

Info

Publication number
EA201300418A1
EA201300418A1 EA201300418A EA201300418A EA201300418A1 EA 201300418 A1 EA201300418 A1 EA 201300418A1 EA 201300418 A EA201300418 A EA 201300418A EA 201300418 A EA201300418 A EA 201300418A EA 201300418 A1 EA201300418 A1 EA 201300418A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
variants
application
tweak
human tweak
Prior art date
Application number
EA201300418A
Other languages
English (en)
Inventor
Моника Бенер
Хендрик Кнётген
Йенс Нивёнер
Original Assignee
Ф.Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ф.Хоффманн-Ля Рош Аг filed Critical Ф.Хоффманн-Ля Рош Аг
Publication of EA201300418A1 publication Critical patent/EA201300418A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Plant Pathology (AREA)

Abstract

В заявке описано антитело, которое связывается с TWEAK, отличающееся тем, что содержит CDR3H вариабельной области тяжелой цепи, выбранный из SEQ ID NO: 8, 16 или 24, которое можно применять для лечения рака или аутоиммунных заболеваний, ревматоидного артрита, псориатического артрита, заболеваний мышц, например мышечной дистрофии, рассеянного склероза, хронических заболеваний почек, заболеваний костей, например дегенерации костной ткани при множественной миеломе, системной красной волчанки, волчаночного нефрита и сосудистого повреждения.
EA201300418A 2010-10-05 2011-09-30 Антитела к человеческому tweak и варианты их применения EA201300418A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10186536 2010-10-05
PCT/EP2011/067070 WO2012045671A1 (en) 2010-10-05 2011-09-30 Antibodies against human tweak and uses thereof

Publications (1)

Publication Number Publication Date
EA201300418A1 true EA201300418A1 (ru) 2013-09-30

Family

ID=43086385

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201300418A EA201300418A1 (ru) 2010-10-05 2011-09-30 Антитела к человеческому tweak и варианты их применения

Country Status (21)

Country Link
US (1) US9187564B2 (ru)
EP (1) EP2625200A1 (ru)
JP (1) JP5941049B2 (ru)
KR (1) KR101584416B1 (ru)
CN (1) CN103154029B (ru)
AR (1) AR083336A1 (ru)
AU (1) AU2011311673B2 (ru)
BR (1) BR112013007293A2 (ru)
CA (1) CA2809632A1 (ru)
CL (1) CL2013000901A1 (ru)
CR (1) CR20130108A (ru)
EA (1) EA201300418A1 (ru)
EC (1) ECSP13012542A (ru)
HK (1) HK1186195A1 (ru)
MA (1) MA34642B1 (ru)
MX (1) MX343114B (ru)
NZ (1) NZ607588A (ru)
PE (1) PE20131411A1 (ru)
SG (1) SG188605A1 (ru)
TW (1) TWI482630B (ru)
WO (1) WO2012045671A1 (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK10042001A3 (sk) * 1999-01-15 2001-12-03 Biogen, Inc. Farmaceutická kompozícia obsahujúca činidlo blokujúce proteín tweak alebo receptor tweak
DK1997512T3 (da) 2002-04-09 2014-01-27 Biogen Idec Inc Fremgangsmåder til behandling af TWEAK-relaterede tilstande
CA2597945C (en) 2005-02-17 2016-07-12 Biogen Idec Ma Inc. Treating neurological disorders
EP1885388B1 (en) 2005-05-10 2013-09-11 Biogen Idec MA Inc. Treating and evaluating inflammatory disorders
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
WO2012116926A1 (en) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Antigen binding proteins
BR112013020338A2 (pt) 2011-02-28 2016-10-18 Hoffmann La Roche proteína de ligação de antígeno monovalente, composição farmacêutica, uso da proteína de ligação de antígeno monovalente, método para o tratamento de um paciente com necessidade de terapia, método para a preparação de uma proteína de ligação de antígeno monovalente, ácido nucleico, vetor e célula hospedeira
SG11201406238UA (en) 2012-04-05 2014-10-30 Hoffmann La Roche Bispecific antibodies against human tweak and human il17 and uses thereof
JP2016000003A (ja) * 2013-04-19 2016-01-07 アステラス製薬株式会社 新規抗ヒトｔｗｅａｋ抗体
US20160243224A1 (en) * 2013-10-04 2016-08-25 Biogen Ma Inc. Tweak antagonists for treating lupus nephritis and muscle atrophy
JP6744292B2 (ja) * 2014-07-29 2020-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性抗体
CN112180100A (zh) * 2020-09-27 2021-01-05 西安交通大学 Tweak作为鉴别不同类型银屑病的分子标志物的应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
JP3537535B2 (ja) 1994-07-14 2004-06-14 株式会社中埜酢店 免疫グロブリンｇ結合糖鎖構造に基づく臨床検査方法
AU7668696A (en) 1995-11-03 1997-05-22 Austin Research Institute, The Methods and compositions for the reduction of xenotransplantation rejection
EP0956351B1 (en) 1996-08-07 2005-10-19 Biogen Idec MA Inc. A tumor necrosis factor related ligand
WO1998033523A1 (en) 1997-01-31 1998-08-06 Biovation Limited Vaccination methods and molecules
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
DE69936946T2 (de) 1998-05-06 2008-05-15 Genentech, Inc., South San Francisco Reinigung von Antikörpern durch Ionenaustauschchromatographie
WO2000034317A2 (en) 1998-12-08 2000-06-15 Biovation Limited Method for reducing immunogenicity of proteins
SK10042001A3 (sk) 1999-01-15 2001-12-03 Biogen, Inc. Farmaceutická kompozícia obsahujúca činidlo blokujúce proteín tweak alebo receptor tweak
DK1997512T3 (da) 2002-04-09 2014-01-27 Biogen Idec Inc Fremgangsmåder til behandling af TWEAK-relaterede tilstande
EP1629012B1 (en) 2003-05-31 2018-11-28 Amgen Research (Munich) GmbH Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
JP4733635B2 (ja) 2003-07-31 2011-07-27 イミューノメディクス、インコーポレイテッド 抗ｃｄ１９抗体
AR045614A1 (es) 2003-09-10 2005-11-02 Hoffmann La Roche Anticuerpos contra el recepctor de la interleuquina- 1 y los usos de los mismos
CA2587018A1 (en) 2004-11-08 2006-05-18 University Of Maryland, Baltimore Tweak as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
CA2597924C (en) 2005-02-15 2018-10-02 Duke University Anti-cd19 antibodies and uses in oncology
WO2006088890A2 (en) 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating stroke
CA2597945C (en) 2005-02-17 2016-07-12 Biogen Idec Ma Inc. Treating neurological disorders
CN102225200A (zh) 2005-03-07 2011-10-26 健泰科生物技术公司 用于调控tweak和fn14活性的方法和组合物
TW200720289A (en) 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof
EP1885388B1 (en) 2005-05-10 2013-09-11 Biogen Idec MA Inc. Treating and evaluating inflammatory disorders
WO2006130429A2 (en) 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Treatment of cancer
PL1888113T3 (pl) 2005-05-27 2014-11-28 Biogen Ma Inc Przeciwciała wiążące TWEAK
EP1904101A4 (en) 2005-06-08 2011-06-15 Univ Duke ANTI-CD19 ANTIBODY THERAPY FOR TRANSPLANTATION
WO2007002223A2 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
AU2006283560B2 (en) 2005-08-19 2011-12-08 Centocor, Inc. Proteolysis resistant antibody preparations
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
WO2008057634A2 (en) 2006-10-26 2008-05-15 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
DE102005060813A1 (de) 2005-12-20 2007-06-28 Rheinisch-Westfälische Technische Hochschule Aachen Selektive Markierung der Glykane von Antikörpern mit modifizierten Nukleotidzuckern als Substrate von rekombinanten Galactosyltransferasen
EP1878747A1 (en) 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-engineered antibodies
US8093006B2 (en) 2009-04-02 2012-01-10 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof

Also Published As

Publication number Publication date
JP2013543383A (ja) 2013-12-05
CN103154029A (zh) 2013-06-12
AU2011311673A1 (en) 2013-03-14
AU2011311673B2 (en) 2015-09-17
BR112013007293A2 (pt) 2016-06-14
MX343114B (es) 2016-10-25
JP5941049B2 (ja) 2016-06-29
AR083336A1 (es) 2013-02-21
US9187564B2 (en) 2015-11-17
CA2809632A1 (en) 2012-04-12
US20120121583A1 (en) 2012-05-17
WO2012045671A1 (en) 2012-04-12
EP2625200A1 (en) 2013-08-14
SG188605A1 (en) 2013-04-30
CN103154029B (zh) 2015-11-25
CL2013000901A1 (es) 2013-11-29
MX2013003592A (es) 2013-05-31
TWI482630B (zh) 2015-05-01
ECSP13012542A (es) 2013-06-28
NZ607588A (en) 2014-02-28
CR20130108A (es) 2013-04-29
KR20130062369A (ko) 2013-06-12
TW201219054A (en) 2012-05-16
PE20131411A1 (es) 2013-12-16
HK1186195A1 (zh) 2014-03-07
MA34642B1 (fr) 2013-11-02
KR101584416B1 (ko) 2016-01-13

Similar Documents

Publication Publication Date Title
EA201300418A1 (ru) Антитела к человеческому tweak и варианты их применения
PH12015501994A1 (en) Antibodies that bind il-23
EA201492149A1 (ru) St2-антигенсвязывающие белки
NZ594315A (en) Antibody molecules having specificity for human ox40
EA200901263A1 (ru) Конденсированный аминопиридин в качестве ингибиторов hsp90
WO2007024846A3 (en) Anit-il-23 antibiodies
EA201591478A1 (ru) Биспецифические антитела против фно и ил-17
WO2010017103A3 (en) Fully human anti-human nkg2d monoclonal antibodies
EA201291067A1 (ru) Гуманизированные антигенсвязывающие белки к миостатину
EA201000424A1 (ru) Антитела к il-23
CY1113640T1 (el) Μεθοδοι για την θεραπευτικη αγωγη ρευματοειδους αρθριτιδας
EA201291161A3 (ru) Связывающие csf1r антитела
MY149129A (en) Anti-sclerostin antibodies
EA201290589A1 (ru) Cd127-связывающие белки
EA202090401A1 (ru) Анти-tim-3 антитела и их применение
EA201290977A1 (ru) Гуманизированные антитела к il-25
IN2012DN01981A (ru)
EA201891800A1 (ru) Антитела к цитруллинированным hla-полипептидам и их применение
TH169590A (th) แอนติบอดีที่ยึดเกาะ il-23
CO6680666A2 (es) Anticuerpos contra la tweak humana y usos de los mismos
TH135279B (th) องค์ประกอบแอนติ-vegfr-3 แอนติบอดี